X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Merck Ltd with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs MYLAN (US) - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 MERCK LTD   MYLAN
EQUITY SHARE DATA
    MERCK LTD
Dec-16
MYLAN
Dec-14
MERCK LTD/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0603,845-   
Low Rs6232,710-   
Sales per share (Unadj.) Rs632.41,316.4-  
Earnings per share (Unadj.) Rs45.7158.6-  
Cash flow per share (Unadj.) Rs62.3255.3-  
Dividends per share (Unadj.) Rs11.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs388.8654.4-  
Shares outstanding (eoy) m16.60378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.32.5 53.4%   
Avg P/E ratio x18.420.7 89.1%  
P/CF ratio (eoy) x13.512.8 105.2%  
Price / Book Value ratio x2.25.0 43.2%  
Dividend payout %24.10-   
Avg Mkt Cap Rs m13,9691,240,152 1.1%   
No. of employees `0001.625.0 6.3%   
Total wages/salary Rs m1,4870-   
Avg. sales/employee Rs Th6,631.919,923.8 33.3%   
Avg. wages/employee Rs Th939.20-   
Avg. net profit/employee Rs Th479.42,400.1 20.0%   
INCOME DATA
Net Sales Rs m10,498498,094 2.1%  
Other income Rs m242-2,903 -8.3%   
Total revenues Rs m10,741495,191 2.2%   
Gross profit Rs m1,135123,878 0.9%  
Depreciation Rs m27636,583 0.8%   
Interest Rs m021,485 0.0%   
Profit before tax Rs m1,10262,907 1.8%   
Minority Interest Rs m0-258 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3432,645 13.0%   
Profit after tax Rs m75960,004 1.3%  
Gross profit margin %10.824.9 43.5%  
Effective tax rate %31.14.2 740.7%   
Net profit margin %7.212.0 60.0%  
BALANCE SHEET DATA
Current assets Rs m6,410437,891 1.5%   
Current liabilities Rs m8,828342,343 2.6%   
Net working cap to sales %-23.019.2 -120.1%  
Current ratio x0.71.3 56.8%  
Inventory Days Days5878 73.9%  
Debtors Days Days38107 35.8%  
Net fixed assets Rs m1,406115,233 1.2%   
Share capital Rs m16617,614 0.9%   
"Free" reserves Rs m6,2860-   
Net worth Rs m6,455247,602 2.6%   
Long term debt Rs m0369,893 0.0%   
Total assets Rs m8,828997,318 0.9%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.20.5 238.1%   
Return on assets %8.68.2 105.2%  
Return on equity %11.824.2 48.5%  
Return on capital %17.113.6 125.3%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Net fx Rs m-1,6530-   
CASH FLOW
From Operations Rs m1,07065,475 1.6%  
From Investments Rs m-750-51,635 1.5%  
From Financial Activity Rs m-150-17,253 0.9%  
Net Cashflow Rs m171-3,413 -5.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.52 Rs / USD

Compare MERCK LTD With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare MERCK LTD With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  CADILA HEALTHCARE  JUBILANT LIFE SCIENCES  STRIDES SHASUN LTD  



Today's Market

Sensex Finishes on a Flat Note; Novartis India Rallies 7%(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement this week.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

The Recipe to Over 60% Returns in Less Than a Year(The 5 Minute Wrapup)

Sep 9, 2017

Short term crisis in some companies could unveil some great investing opportunities.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 21, 2017 03:37 PM

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS